Overexpression of EZH2 has been observed in lymphomas, sarcomas, and cancers of the breast, colon, liver, lung, and prostate (Chang and Hung, 2012; Han et al., 2020; Li et al., 2009; Sauvageau and Sauvageau, 2010; Yamaguchi and Hung, 2014). Here, EZH2 is linked to lymphoma.